Floatz Rating
B56/100
Confidence
Indicative
Sponsor
Xynomic Pharmaceuticals, Inc.
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
55High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05275374CT.gov XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 Mutation | — | Not Yet Recruiting | — | — | — |
NCT06229340CT.gov Leflunomide or Combination of MEK Inhibitor and Hydroxychloroquine for Refractory Patients With RAS Mutations | — | Recruiting | — | — | — |
NCT05668585CT.gov A Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and Combination Therapy in Subjects With BRAF V600 Mutant Solid Tumors | — | Completed | — | — | — |
NCT05358249CT.gov Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation | — | Active Not Recruiting | — | — | — |
NCT04294160CT.gov A Study of Select Drug Combinations in Adult Patients With Advanced/Metastatic BRAF V600 Colorectal Cancer | — | Terminated | — | — | — |
NCT03714958CT.gov Trametinib + HDM201 in CRC Patients With RAS/RAF Mutant and TP53 Wild-type Advanced/Metastatic Colorectal Cancer Mutant and TP53 Wild-type | — | Completed | — | — | — |
NCT03668431CT.gov Dabrafenib + Trametinib + PDR001 In Colorectal Cancer | — | Unknown | — | — | — |
NCT04303403CT.gov Study of Trametinib and Ruxolitinib in Colorectal Cancer and Pancreatic Adenocarcinoma | — | Unknown | — | — | — |
NCT03317119CT.gov Trametinib and Trifluridine and Tipiracil Hydrochloride in Treating Patients With Colon or Rectal Cancer That is Advanced, Metastatic, or Cannot Be Removed by Surgery | — | Completed | — | — | — |
NCT03428126CT.gov Study of Durvalumab (MEDI4736) (Anti-PD-L1) and Trametinib (MEKi) in MSS Metastatic Colon Cancer | — | Completed | — | — | — |
Show 6 more trialsShow fewer
NCT03377361CT.gov An Investigational Immuno-therapy Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Participants With Previously Treated Cancer of the Colon or Rectum That Has Spread | — | Completed | — | — | — |
NCT03087071CT.gov Panitumumab With or Without Trametinib in Treating Patients With Stage IV Colorectal Cancer | — | Active Not Recruiting | — | — | — |
NCT02703571CT.gov Study of Safety and Efficacy of Ribociclib and Trametinib in Patients With Metastatic or Advanced Solid Tumors | — | Terminated | — | — | — |
NCT02538627CT.gov Phase 1 Combination Study of MM-151 With MM-121, MM-141, or Trametinib | — | Terminated | — | — | — |
NCT02399943CT.gov A Trial of Trametinib and Panitumumab in RAS/RAF Wild Type Advanced Colorectal Cancer | — | Completed | — | — | — |
NCT02230553CT.gov Lapatinib Plus Trametinib in KRAS Mutant NSCLC | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Colorectal Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Trametinib (this asset) | Xynomic Pharmaceuticals, Inc. | P2 | B · 56 |
| Desflurane | Peter MacCallum Cancer Centre, Australia | P4 | BBB |
| Marble Dust | James Varani | P2/3 | BB |
| Oxaliplatin | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | P4 | BB |
| Orectalip | Sinphar Pharmaceutical Co., Ltd | P4 | BB |
| Fluorouracilum | UNICANCER | P4 | BB |
| Levofolinic Acid | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | P3 | BB |
| Fentanyl | Mansoura University | P4 | BB |
| Panitumumab | MSPU des 3 Provinces | P3 | BB |
+42 more in the Colorectal Cancer cohort
Other indications for Trametinib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Melanoma | — | P4 | BB · 69 |
| Anaplastic Pleomorphic Xanthoastrocytoma | — | P4 | BB · 69 |
| Anaplastic Oligodendroglioma | — | P4 | BB · 69 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Trametinib in Colorectal Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/trametinib-colorectal-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →